TY - JOUR
T1 - Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
AU - Tebas, Pablo
AU - Powderly, William G.
AU - Claxton, Sherry
AU - Marin, Donna
AU - Tantisiriwat, Woraphot
AU - Teitelbaum, Steven L.
AU - Yarasheski, Kevin E.
PY - 2000
Y1 - 2000
N2 - Background: The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time. Methods: We performed a cross-sectional analysis of whole-body, lumbar spine (L1-L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry. Results: Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13-4.23) (P = 0.02). Subjects receiving protease inhibitors had greater central:appendicular adipose tissue ratios than the other two groups (P < 0.0001). There was no relationship between the central:appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t- or z- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART. Conclusions: Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution. (C) 2000 LippincottWilliams and Wilkins.
AB - Background: The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time. Methods: We performed a cross-sectional analysis of whole-body, lumbar spine (L1-L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry. Results: Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13-4.23) (P = 0.02). Subjects receiving protease inhibitors had greater central:appendicular adipose tissue ratios than the other two groups (P < 0.0001). There was no relationship between the central:appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t- or z- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART. Conclusions: Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution. (C) 2000 LippincottWilliams and Wilkins.
KW - Adiposity
KW - Aspartyl protease inhibitors
KW - Bone densitometry
KW - Bone mineral metabolism
KW - HIV infection
KW - Osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=0034031191&partnerID=8YFLogxK
U2 - 10.1097/00002030-200003100-00005
DO - 10.1097/00002030-200003100-00005
M3 - Article
C2 - 10770534
AN - SCOPUS:0034031191
SN - 0269-9370
VL - 14
SP - F63-F67
JO - AIDS
JF - AIDS
IS - 4
ER -